促性腺激素释放激素激动剂治疗子宫肌瘤及对免疫功能的影响

Effect of gonadotropin-releasing hormone agonist on uterine fibroids and its effect on immune function

目的探讨促性腺激素释放激素激动剂（GnRH-a）治疗子宫肌瘤及对免疫功能的影响。方法选取2016年1月~2016年12月天津医科大学第二医院收治的子宫肌瘤患者130例,随机分为2组,对照组应用米非司酮治疗,研究组应用GnRH-a治疗。结果治疗前2组患者的子宫大小以及肌瘤大小无明显区别,治疗后均得到一定改善,研究组显著小于对照组（P〈0.05）;治疗前2组患者的血清性激素水平无明显区别,治疗后均得到一定改善,研究组显著优于对照组（P〈0.05）;治疗前2组患者的免疫功能水平无明显区别,治疗后均得到一定改善,研究组显著优于对照组（P〈0.05）。结论子宫肌瘤患者应用GnRH-a治疗有利于提高疗效果,改善患者的血清性激素水平以及免疫功能。

Objective To investigate the hysteromyoma treated with the gonadotropin releasing hormone agonist（ GnRH-a） and the impact on immunologic function. Methods 130 cases selected from the patients with hysteromyoma enrolled from January 2016 to December 2016 in hospital have been randomly divided into two groups. The control group has been treated with mifepristone while the study group GnRH-a. Results The sizes of uterus and myoma of both groups have no significant difference before treatment. After treatment,both of them are significantly improved,and those of the study group is significantly smaller than that of the control group（ P 〈0. 05）. The levels of serum sex hormone and immunologic function of both groups have no significant difference before treatment. They are both improved after treatment,and the study group is significantly better than the control group（ P〈 0. 05）. Conclusion Applying GnRH-a therapy to the patients with uterine myoma benefits for improving the therapeutic effect,which can improve the serum sex hormone levels and immunologic function.